Background: Proton pump inhibitors (PPI) are often used in patients with gastro-
1 This is the rationale for their regular use in patients with gastroesophageal reflex disease (GERD) and peptic ulcer disease.
Apart from these well-defined indications, the Food and Drug Adminstration (FDA) recommends PPI therapy for patients with Zollinger-Ellison syndrome, for healing and maintenance of erosive oesophagitis and for risk reduction in patients with regular need for treatment with non-steroidal antiinflammatory drugs (NSAIDS) as well as in combination with antibiotics for treatment of helicobacter pylori infection. 2 PPIs are generally well tolerated as they have few adverse events such as flatulence, headache, diarrhoea and abdominal pain which are often self-limiting. 1 In contrast to these welldefined indications, PPIs are also used for treatment of unspecific abdominal pain and discomfort, often as over-the-counter drugs without any medical consultation. This leads to an increasing and often inappropriate use of PPIs which are currently among the most commonly used drugs. 3 However, during the last years, there have been several reports revealing negative long-term effects of PPI treatment. Their use was associated with development of pneumonia caused by reduced gastric acidity which may facilitate bacterial overgrowth leading to pneumonia due to microaspiration. 1 In addition, an association of PPI treatment with an increased risk for C. difficile infection, hepatic encephalopathy 4 and spontaneous bacterial peritonitis in patients with liver cirrhosis have been reported. 5 Furthermore, some analyses found associations of PPI use with an increased risk for dementia, 6 ,7 myopathy [8] [9] [10] and acute kidney injury. 11, 12 Recently, two population-based case-control studies demonstrated a strong association of PPI treatment with the development of pyogenic liver abscesses. 13, 14 Since many patients who are hospitalised for pyogenic liver abscess have ongoing PPI treatment and since previous studies have shown an increased mortality in patients with ongoing PPI treatment in infectious diseases, 5 we set out to analyse the prognostic effect of PPI treatment in patients with newly diagnosed pyogenic liver abscess.
| PATIENTS AND METHODS

| Selection of patients
Between January 2005 and March 2017, all patients (n = 181) with pyogenic liver abscess and available information regarding diagnosis, treatment and the clinical course were included in this retrospective, observational study. Clinical, microbiological, laboratory and imaging data were retrieved from the electronic medical patient records.
Patients were followed-up until end of hospitalisation and/or first out-patient visit after hospital discharge. The mean follow-up was 
| Ethics approval
This study was performed in accordance with the Declaration of Helsinki and it was approved by the local ethics committee of the University Hospital of Freiburg (no. EK 513/17).
| Statistical analyses
Baseline characteristics of the patients were analysed at diagnosis of pyogenic liver abscess and patients had follow-up for 90 days after hospitalisation. Continuous variables are expressed as mean and the corresponding standard deviation, whereas categorial variables are reported as frequencies and percentages unless stated otherwise.
For continuous variables, differences were determined using Wil- 3 | RESULTS
| Patient characteristics
In total, 181 patients with pyogenic liver abscess were included in the analyses. Table 1 With regard to clinical presentation at diagnosis of pyogenic liver abscess, there were no significant differences between patients with or without PPI. Fever was the most common symptom in both patient groups (52.0% vs 65.4%, P = 0.072). Furthermore, 59.0% of patients with PPI intake had an active tumour disease compared to 49.4% of the patients in the non-PPI-intake group (P = 0.876). Thirty-seven of the 100 patients taking PPI (37.0%) had bile duct compression with intrahepatic cholestasis compared to 26 patients in the non-PPI group (32.1%, P = 0.532). Moreover, immunosuppressive treatment was given in 28.0% vs 16.0% in the PPI vs non-PPI group (P = 0.074).
The mean duration of the hospital stay was 27 days (median: 17 During hospitalisation, 29% of the PPI group had to be transferred to the intensive care unit compared to 21% of the non-PPI users.
The main reason for intensive care treatment was septic shock (15.0% vs 14.8%) and the mean duration of intensive care treatment was 12 AE 20 days (11 AE 23 days in patients without PPI intake compared to 10 AE 18 days in patients with PPI intake, P = 0.871).
| Microbiological findings in PPI-takers vs non-PPI-takers with pyogenic liver abscess
At diagnosis of pyogenic liver abscess, 46 of 100 patients (46%) with PPI treatment had positive blood culture compared to 27 of 81 patients (33%) with no PPI treatment (P = 0.137). In these blood cultures, 56 isolates could be cultured in patients with PPI intake. In total, 121 of 181 patients (66.9%) were treated with percutaneous drainage and microbiological culture was performed from of the extracted pus. In patients with PPI intake, 131 isolates were found in the abscess culture. Table 2 summarises the pathogens isolated in the blood and abscess culture in both patient groups. In summary,
there were no significant differences in identified pathogens and their distribution either in blood or abscess cultures in patients with and without PPI intake.
Moreover, there were no significant differences between the two groups regarding the identification of multidrug resistant bacteria in blood or abscess samples ( Figure S1 ).
| Management of patients with pyogenic liver abscess
After diagnosis of pyogenic liver abscess 121 of 181 patients (66.9%) underwent percutaneous drainage of the liver abscess. The mean duration of abscess drain of the liver abscess was 13 AE 19 days (12 AE 17 days in patients without PPI intake compared to 13 AE 21 days in patients with PPI intake, P = 0.792).
All patients received antibiotic treatment with the duration of treatment ranging from 7 to 43 days. 106 of the patients (58.6%)
were treated with a combination of antibiotic agents, mainly a combination of beta-lactam with or without beta-lactamase inhibitors, carbapenems or third generation cephalosporins and metronidazol.
3.4 | Patients with PPI intake and pyogenic liver abscess have higher index mortality and 90-day mortality compared to patients without PPI intake
During hospitalisation, 39 of 181 patients (21.5%) died. Eighteen of 39 patients (46.2%) died due to septic shock. In two patients (5.1%), uncontrolled bleeding after percutaneous drain insertion of the liver abscess occurred and these patients died due to hemorrhagic shock.
Fourteen patients (35.9%) died due to progressive tumour disease and three patients (7.7%) died as liver function deteriorated significantly during the infection. Stratified to patients with and without PPI intake nine of 81 patients without PPI intake (11.1%) died compared to 28 of 100 patients (30.0%) in the PPI intake group (P = 0.003, Figure 1A ). In patients with PPI intake 14 patients (14%) died due to septic shock compared to 6 patients (7.4%) in the group without PPI intake (P = 0.451). Although being not statistically significant, we observed a trend for a more severe course of the infection in patients with PPI intake. There were no significant differences in further reasons of death between the PPI and non-PPI group (Table S3) . With regard to the dose of PPI, we observed an index
Characteristics
No proton pump inhinitor intake n = 81 Proton pump inhibitor intake n = 100 P value The patient in the non-PPI group had hepatic metastatic colorectal cancer at the time of diagnosis of liver abscess (UICC stage IV).
c One patient had colorectal cancer staged as UICC I (T1N0M0). The remaining patients were staged as UICC IV with hepatic metastases. Only in one patient liver abscess may be associated with hepatic metastases. In all other patients, no local association with metastases and liver abscesses were observed. Multivariate analysis confirmed that treatment with PPI at admission and treatment during hospitalisation is a significant, comorbidity-independent, predictive factor for index mortality in patients with pyogenic liver abscess (Odds ratio 2.56 [1.01-6.46], P = 0.039); Table 3 ).
Furthermore, we evaluated the 90-day-mortality rate in patients treated with and without PPI treatment. During the following 90 days after hospitalisation, 38 patients with PPI intake (38.0%)
had died compared to 14 patients (17.3%) without PPI treatment (P = 0.003, Figure 1B) . patients with liver cirrhosis. 5, 16, 17 Recently, two population-based case-control studies showed an association with an increased risk of pyogenic liver abscess. 13, 14 As many patients being admitted to the hospital due to pyogenic liver abscess are treated with PPI, we set out to analyse the impact of PPI treatment on the clinical course and mortality in patients with pyogenic liver abcesses. 
T A B L E 2
F I G U R E 1 Index mortality and 90-day-mortality in patients with pyogenic liver abscess stratified to PPI intake. A Patients with proton pump inhibitor treatment had significantly higher index mortality compared to patients without proton pump inhibitor treatment (30.0% vs 11.1%, P = 0.003). B During 90-day-follow-up 38 patients with proton pump inhibitor treatment died (38.0%) compared to 14 patients (17.3%) without proton pump inhibitor treatment (P = 0.003)
The higher risk for development of pyogenic liver abscess has been explained by bacterial overgrowth in the duodenum and colon resulting in increased bacterial translocation and migration of bacteria through the portal vein in the liver. 14 Noteworthly, these mechanisms are the similar to the ones described in patients with liver cirrhosis showing a higher risk for spontaneous bacterial peritonitis during PPI treatment. Several studies in these patients have shown a possible association with increased mortality although these data are conflicting. 5, 18, 19 In contrast to patients with liver cirrhosis and spontaneous bacterial peritonitis, there have been no studies focusing on the prognostic role of PPI treatment in patients with pyogenic liver abscess. In our study, we were able to show an increased index mortality in PPI takers compared to patients without PPI treatment (11.1% vs 30.0%, P = 0.003). This significant difference with an odds ratio of 2.56 was still present after adjusting for comorbidities represented by the Charlson index, hepatic extension of the abscess and requirement for ICU treatment in a multivariate logistic regression model. However, we
were not able to assess the role of PPI treatment on overall survival as we had few survival data after hospitalisation of our patients. Therefore, this important question still needs to be clarified in well-powered prospective, randomised, controlled trials.
The biological and pathophysiological mechanism which may explain the higher mortality in PPI treated patients also requires clarification. Importantly, it has been shown that PPIs have antioxidant and anti-inflammatory functions which may play an important additional role in controlling infection. Zedtwitz-Liebenstein et al reported that omeprazole in vitro impairs the production of reactive oxygen species in neutrophils. 20 Apart from a PPI mediated attenuation of free radical production in immune cells by PPIs, 21, 22 there have been several reports showing an anti-inflammatory effect of PPIs. These drugs may play an important role in the regulation of chemotaxis and phagocytosis. 23 Moreover, PPI may affect transmigration of leucocytes from vessels to the inflammatory site as they may hamper the activation of the heparanase that is an essential enzyme in this process. 24 This is explained by an increasing intralysosomal pH resulting in reduced activation of the heparanase. 23 It has also been shown that PPI in clinically relevant doses can inhibit the expression of CD11b and CD18 on neutrophils. These molecules are Our study has several limitations. We performed a single center study with a small sample size and therefore our results need external validation. The primary endpoint of our study was index mortality and 90-day mortality as we were not able to assess overall survival due to missing long-term survival data. This important issue should be reassessed in randomised, controlled trials. Furthermore, patients with PPI intake had significantly higher Charlson indices representing significantly more comorbidities in these patients. However, to adjust for this confounder, we performed multivariate logistic regression model and PPI treatment was still an independent predictive factor. Importantly, owing to the retrospective design, we only describe an Uni-and multivariate logistic regression model shows that PPI intake is significantly associated with higher index mortality.
association of PPI intake with a higher mortality any conclusion on mechanistic causality of PPI intake cannot be drawn. Moreover, there was no clear dose-dependent effect of PPI treatment on mortality as most of the PPI intakers were treated with 40 mg (72.0%). Finally, it was often difficult to accurately assess the duration of PPI treatment before diagnosis of pyogenic liver abscess which may also have a significant impact on index mortality. PPI treatment was only stopped in few patients during hospitalisation. Due to the small numbers, we
were not able to assess if cessation of PPI treatment may lead to a decreased mortality compared to patients with ongoing PPI treatment.
Being aware of the limitations of our study, we were able to show that PPI treatment in patients with pyogenic liver abscess is associated with higher index mortality. Together with previous data on higher incidence of liver abscesses in patients with PPI therapy, our study underlines the importance to critically evaluate (and reevaluate) PPI indications in patients with pyogenic liver abscesses.
Importantly, previous studies in patients with infectious diseases have shown higher mortality rates in PPI-treated patients and therefore our study is in line with these findings. In summary, our study may sensibilise clinicians for critical prescription of PPIs in patients with a higher risk of pyogenic liver abscess such as patients with hepatic metastatic tumour disease, advanced liver disease and immunosuppressive treatment.
